Jnana Therapeutics, a biotechnology company leveraging its next-gen chemoproteomics platform to discover medicines for challenging-to-drug targets, has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a range of target classes to address diseases with high unmet need.   Jnana will receive $50 million upfront, near-t...